Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency

被引：18
|
作者：
Naderi, M. [1 ]
Dorgalaleh, A. [2 ]
Alizadeh, S. [2 ]
Kashani Khatib, Z. [2 ]
Tabibian, S. [2 ]
Kazemi, A. [2 ]
Dargahi, H. [2 ]
Bamedi, T. [1 ]
机构：
[1] Zahedan Univ Med Sci, Ali Ebn E Abitaleb Hosp Res Ctr Adolescents Hlth, Zahedan, Iran
[2] Univ Tehran Med Sci, Allied Med Sch, Dept Hematol, Tehran 141556183, Iran
来源：
HAEMOPHILIA | 2014年 / 20卷 / 01期
关键词：
COAGULATION; IRAN; TAFI;
D O I：
10.1111/hae.12287
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E89 / E92
页数：4
相关论文
共 50 条
  • [1] POLYMORPHISM OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR AND RISK OF INTRACRANIAL HEMORRHAGE IN FACTOR XIII DEFICIENCY
    Dorgalaleh, A.
    Alizadeh, S.
    Naderi, M.
    Kazemi, A.
    Tabibian, S.
    Khatib, Z.
    HAEMATOLOGICA, 2013, 98 : 743 - 743
  • [2] Thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2335 - 2348
  • [3] Deficiency of Thrombin-activatable Fibrinolysis Inhibitor Worsens Bronchial Asthma
    Takagi, T.
    Urawa, M.
    Naitou, M.
    Fujiwara, A.
    Ebihara, A.
    Kobayashi, T.
    Kobayashi, H.
    D'Alessandro-Gabazza, C. N.
    Gabazza, E. C.
    Taguchi, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [4] Is there thrombin-activatable fibrinolysis inhibitor in saliva?
    Chopra, S.
    Friman, E.
    Krueger, C. W.
    Antovic, J. P.
    Naimi-Akbar, A.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2020, 58 (09): : E33 - E37
  • [5] Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis
    Lisman, T
    Leebeek, FWG
    Mosnier, LO
    Bouma, BN
    Meijers, JCM
    Janssen, HLA
    Nieuwenhuis, HK
    De Groot, PG
    GASTROENTEROLOGY, 2001, 121 (01) : 131 - 139
  • [6] Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
    Eichinger, S
    Schönauer, V
    Weltermann, A
    Minar, E
    Bialonczyk, C
    Hirschl, M
    Schneider, B
    Quehenberger, P
    Kyrle, PA
    BLOOD, 2004, 103 (10) : 3773 - 3776
  • [7] Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life
    Nagashima, M
    Yin, ZF
    Zhao, L
    White, K
    Zhu, YH
    Lasky, N
    Halks-Miller, M
    Broze, GJ
    Fay, WP
    Morser, J
    JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (01): : 101 - 110
  • [8] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, C. J. N.
    Nieuwdorp, M.
    Gerdes, V. E. A.
    Morgelin, M.
    Meijers, J. C. M.
    Marx, P. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 392 - 392
  • [9] Characterization of mouse thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    Wagenaar, GTM
    Reijerkerk, A
    Tiekstra, MJ
    van Rossum, AGSH
    Gebbink, MFBG
    Meijers, JCM
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 297 - 303
  • [10] Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia
    Verkleij, Chantal J. N.
    Stuijver, Danka J. F.
    van Zaane, Bregje
    Squizzato, Alessandro
    Brandjes, Dees P. M.
    Buller, Harry R.
    Meijers, Joost C. M.
    Gerdes, Victor E. A.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (02) : 214 - 220
12345